SCHEMBL27207461

SCHEMBL27207461

CC1CC(=O)c2c(ccc(F)c2F)O1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.46
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
GAA P10253 1/20 0.40
ALPG P10696 1/20 0.40
THRB P10828 1/20 0.40
APEX1 P27695 1/20 0.40
MAPK1 P28482 1/20 0.40
RECQL P46063 1/20 0.40
GCGR P47871 1/20 0.40
RAB9A P51151 1/20 0.40
VCP P55072 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27203904 1.00 PBRM1 (0.46) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL27203856 1.00 PBRM1 (0.46) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL9818910 0.84 PBRM1 (0.51) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL27203906 0.80 BRD4 (0.44) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL25207401 0.73 KDM4E (0.47) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL9819147 0.73 PBRM1 (0.46) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL30964228 0.71 BRD4 (0.45) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL7609607 0.71 BRD4 (0.45) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL28813644 0.70 MAOA (0.59) PBRM1ALDH1A1KDM4EMAPTPOLB
SCHEMBL2106757 0.70 PBRM1 (0.67) PBRM1ALDH1A1KDM4EMAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 US disclosed
US-20240132490-A1 INHIBITORS OF PROTEIN KINASE A BLUEPRINT MEDICINES CORPORATION (US) 2024-04-25 US disclosed
WO-2022165402-A1 INHIBITORS OF PROTEIN KINASE A BLUEPRINT MEDICINES CORPORATION (US) 2022-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583856-B2 Inhibitors of protein kinase A CSNK1A1, CSNK1A1L, CSNK1G1 PBRM1 1534/4885ALDH1A1 2595/4885KDM4E 1891/4885
US-20240132490-A1 INHIBITORS OF PROTEIN KINASE A PRKCA, MAP3K6, MAP3K1 PBRM1 1719/4885ALDH1A1 2528/4885KDM4E 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.